Company news

Quanterix Corporation news in 2024

Quanterix Corporation's news releases, calls and decks from 2024, newest first.

View company

Quanterix Releases Preliminary Financial Results for the Third Quarter of 2024

November 11, 2024

Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors

October 1, 2024

Quanterix Announces Commercialization of p-Tau 217 Test Kit

September 29, 2024

Quanterix Releases Financial Results for the Second Quarter of 2024

August 7, 2024

Quanterix To Report Second Quarter 2024 Financial Results

July 30, 2024

Quanterix Presents Data Demonstrating Successful Multi-Marker Approach for Alzheimer’s Disease Detection that is More Effective than Standalone Plasma p-Tau 217

July 28, 2024

Quanterix Releases Financial Results for the First Quarter of 2024

May 6, 2024

Quanterix To Report First Quarter 2024 Financial Results

April 28, 2024

Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease

March 3, 2024

Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023

February 28, 2024

Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance

February 25, 2024

Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer’s Disease

February 25, 2024

Calls in 2024

Decks in 2024